Next-gen muscle-preserving drugs eyed as complement to weight-loss pens

A new class of experimental drugs aims to preserve or increase muscle mass during weight loss, potentially complementing GLP-1-based therapies like semaglutide and tirzepatide. The development is in early stages, with no clinical data or regulatory milestones reported. It signals a strategic shift in obesity treatment toward body composition, not just weight reduction, which could reshape the competitive landscape for pharma.